Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

@article{Chen2014BrentuximabVI,
  title={Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.},
  author={Robert W. Chen and Joycelynne Palmer and N Tsai and Sandra H. Thomas and Tanya Siddiqi and Leslie L Popplewell and Len Farol and Auayporn P. Nademanee and Stephen J. Forman},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2014},
  volume={20 11},
  pages={1864-8}
}
We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to 2012 with BV before RIC-alloHCT with a uniform fludarabine/melphalan conditioning regimen and donor source after a median follow-up of 29.9 months. We have also retrospectively compared… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 9 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…